Genmab — Februar 2019
-
Genmab har været i nedtur i lang tid efterhånden. Men på det seneste er det væltet ind med gode nyheder, og aktien er steget næsten 40% sidenbunden.
Nu er det gode spørgsmål så om beartrenden er endegyldig brudt eller om der skal mere til. Det kigger Hans-Henrik på i videoen her. http://www.proinvestor.com/debat/76708
-
God morgen
-
God morgen.
-
from Halozyme earnings report "ENHANZE
partner Janssen continued to make progress in clinical studies for a subcutaneous co-formulation of Darzalex (daratumumab) with the recent initiation of two additional Phase 3 trials. Janssen is planning regulatory filings in the second half of 2019." -
-
-
Lidt underlig anbefaling med samme kursmål som tidligere.
-
Det sker ofte.
-
Det kan også være at det blot har været en hård lille-fredagsbar i går
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind